SANUWAVE Health (SNWV) 10-Q12 Aug 222022 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2022	Aug. 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Document Transition Report	false
Entity File Number	000-52985
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	0001417663
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	20-1176000
Entity Address, Address Line One	3360 Martin Farm Road
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Suwanee
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30024
City Area Code	770
Local Phone Number	419-7525
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		548,737,651

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 1,484	$ 619
Accounts receivable, net of allowance for doubtful accounts of $0.8 million, respectively	1,749	2,415
Inventory	925	1,040
Prepaid expenses and other current assets	1,181	326
Total Current Assets	5,339	4,400
Property, Equipment and Other, net	535	1,118
Other Intangible Assets, net	5,489	5,841
Goodwill	7,260	7,260
Total Assets	18,623	18,619
Current Liabilities:
Senior secured promissory note payable, in default	12,334	11,586
Convertible promissory notes payable, in default	6,523	11,601
Convertible promissory notes, related parties, in default	1,596	1,596
Short-term loans	1,484	0
Advances on future cash receipts	398	446
Accounts payable	7,083	7,644
Accrued expenses	5,900	4,394
Accrued employee compensation	4,264	4,247
Due under factoring agreement	1,792	1,737
Warrant liability	5,295	9,614
Current portion of SBA loans	272	158
Accrued interest	3,600	2,521
Accrued interest, related parties	402	289
Current portion of lease liabilities	185	268
Current portion of contract liabilities	64	48
Other	107	114
Total Current Liabilities	51,299	56,263
Non-current Liabilities
SBA loans	761	875
Lease liabilities	40	118
Contract liabilities	295	293
Deferred tax liability	28	28
Total Non-current Liabilities	1,124	1,314
Total Liabilities	52,423	57,577
Commitments and Contingencies (Footnote 11)
STOCKHOLDERS' DEFICIT
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175, 293, 90 and 8 shares designated Series A, Series B, Series C and Series D, respectively; no shares issued and outstanding at June 30, 2022 and December 31, 2021	0	0
Common Stock, par value $0.001, 800,000,000 shares authorized; 529,293,205 and 481,619,621 issued and outstanding at June 30, 2022 December 31, 2021, respectively	529	482
Additional Paid-in Capital	151,409	144,582
Accumulated Deficit	(185,671)	(183,949)
Accumulated Other Comprehensive Loss	(67)	(73)
Total Stockholders' Deficit	(33,800)	(38,958)
Total Liabilities and Stockholders' Deficit	$ 18,623	$ 18,619

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Accounts receivable, allowance for doubtful accounts	$ 0.8	$ 0.8
STOCKHOLDERS' DEFICIT
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	800,000,000	800,000,000
Common stock, shares issued (in shares)	529,293,205	481,619,621
Common stock, shares outstanding (in shares)	529,293,205	481,619,621
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	6,175	6,175
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	293	293
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	90	90
Series D Convertible Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock, shares authorized (in shares)	8	8

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total Revenue	$ 3,882	$ 2,909	$ 7,077	$ 5,025
Cost of Revenues	1,096	1,048	1,986	2,103
Gross Margin	2,786	1,861	5,091	2,922
Operating Expenses:
General and administrative	2,937	2,923	5,078	6,045
Selling and marketing	1,672	2,520	3,387	4,300
Research and development	171	272	337	626
Gain on sale of property and equipment, net	(136)	0	(690)	0
Depreciation and amortization	210	192	386	391
Total Operating Expenses	4,854	5,907	8,498	11,362
Operating Loss	(2,068)	(4,046)	(3,407)	(8,440)
Other Income (Expense):
Interest expense	(2,826)	(1,437)	(5,903)	(2,559)
Interest expense, related party	(56)	(48)	(112)	(95)
Change in fair value of derivative liabilities	7,861	(591)	11,343	44
Loss on issuance of debt	0	(2,484)	(3,434)	(2,484)
Loss on extinguishment of debt	(211)	0	(211)	0
Gain / (loss) on foreign currency exchange	2	(3)	2	4
Other Income (Expense), net	4,770	(4,563)	1,685	(5,090)
Net Loss before Income Taxes	2,702	(8,609)	(1,722)	(13,530)
Provision for Income Taxes	0	6	0	22
Net Income (loss)	2,702	(8,615)	(1,722)	(13,552)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	0	(3)	0	(11)
Total Comprehensive Income (Loss)	$ 2,702	$ (8,618)	$ (1,722)	$ (13,563)
Gain (loss) per Share:
Basic (in dollars per share)	$ 0.01	$ (0.02)	$ 0	$ (0.03)
Diluted (in dollars per share)	$ 0	$ (0.02)	$ 0	$ (0.03)
Weighted average shares outstanding, basic and diluted
Basic (in shares)	538,560,051	518,310,781	532,589,825	518,400,008
Diluted (in shares)	871,984,091	518,310,781	532,589,825	518,400,008
Accessory and Parts Revenue [Member]
Revenues:
Total Revenue	$ 2,663	$ 2,008	$ 4,854	$ 3,579
Product [Member]
Revenues:
Total Revenue	862	514	1,507	767
Rental Income [Member]
Revenues:
Total Revenue	344	276	688	530
License Fees and Other [Member]
Revenues:
Total Revenue	$ 13	$ 111	$ 28	$ 149

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning balance at Dec. 31, 2020	$ 0	$ 471	$ 142,563	$ (156,690)	$ (62)	$ (13,718)
Beginning balance (in shares) at Dec. 31, 2020	0	470,694,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cashless warrant exercise	$ 0	$ 11	(11)	0	0	0
Cashless warrant exercise (in shares)	0	10,925,000
Reclassification of warrant liability due to cashless warrant exercise	$ 0	$ 0	2,030	0	0	2,030
Reclassification of warrant liability due to cashless warrant exercise (in shares)	0	0
Net income (loss)	$ 0	$ 0	0	(13,552)	0	(13,552)
Foreign currency translation adjustment	0	0	0	0	(12)	(12)
Ending balance at Jun. 30, 2021	$ 0	$ 482	144,582	(170,242)	(74)	(25,252)
Ending balance (in shares) at Jun. 30, 2021	0	481,619,621
Beginning balance at Mar. 31, 2021	$ 0	$ 482	144,582	(161,627)	(70)	(16,633)
Beginning balance (in shares) at Mar. 31, 2021	0	481,619,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	$ 0	$ 0	0	(8,615)	0	(8,615)
Foreign currency translation adjustment	0	0	0	0	(4)	(4)
Ending balance at Jun. 30, 2021	$ 0	$ 482	144,582	(170,242)	(74)	(25,252)
Ending balance (in shares) at Jun. 30, 2021	0	481,619,621
Beginning balance at Dec. 31, 2021	$ 0	$ 482	144,582	(183,949)	(73)	(38,958)
Beginning balance (in shares) at Dec. 31, 2021	0	481,619,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cashless warrant exercise	$ 0	$ 14	2,152	0	0	2,166
Cashless warrant exercise (in shares)		14,000,000
Warrant exercise	$ 0	$ 1	99	0	0	100
Warrant exercise (in shares)	0	909,091
Shares issued in conjunction with Note Payable	$ 0	$ 20	3,700	0	0	3,720
Shares issued in conjunction with Note Payable (in shares)	0	20,666,993
Shares issued for services		$ 12	876	0	0	888
Shares issued for services (in shares)		12,097,500
Net income (loss)	$ 0	$ 0	0	(1,722)	0	(1,722)
Foreign currency translation adjustment	0	0	0	0	6	6
Ending balance at Jun. 30, 2022	$ 0	$ 529	151,409	(185,671)	(67)	(33,800)
Ending balance (in shares) at Jun. 30, 2022	0	529,293,205
Beginning balance at Mar. 31, 2022	$ 0	$ 517	150,533	(188,373)	(73)	(37,396)
Beginning balance (in shares) at Mar. 31, 2022	0	517,195,705
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued for services	$ 0	$ 12	876			888
Shares issued for services (in shares)	0	12,097,500
Net income (loss)	$ 0	$ 0	0	2,702	0	2,702
Foreign currency translation adjustment	0	0	0	0	6	6
Ending balance at Jun. 30, 2022	$ 0	$ 529	$ 151,409	$ (185,671)	$ (67)	$ (33,800)
Ending balance (in shares) at Jun. 30, 2022	0	529,293,205

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows - Operating Activities:
Net income (loss)	$ (1,722)	$ (13,552)
Adjustments to reconcile net loss to net cash used by operating activities
Amortization of intangibles	352	352
Depreciation	94	198
Bad debt expense	52	240
Income tax expense	0	22
Shares issued for services	888	0
Loss on extinguishment of debt	211	0
Gain on sale of property and equipment, net	(541)	0
Change in fair value of derivative liabilities	(11,343)	(44)
Loss on issuance of debt	3,434	2,484
Amortization of debt issuance costs and original issue discount	1,304	719
Accrued interest	1,078	390
Interest payable, related parties	112	95
Changes in operating assets and liabilities
Accounts receivable - trade	733	218
Inventory	115	521
Prepaid expenses	(855)	(191)
Other assets	47	(83)
Accounts payable	(562)	1,475
Accrued expenses	1,407	1,350
Accrued employee compensation	103	553
Contract liabilities	(108)	4
Net Cash Used by Operating Activities	(5,201)	(5,249)
Cash Flows - Investing Activities
Proceeds from sale of property and equipment	948	0
Purchase of property and equipment	0	(277)
Net Cash Flows Used in Investing Activities	948	(277)
Cash Flows - Financing Activities
Proceeds from senior promissory notes	2,940	1,263
Proceeds from short term notes	2,130	1,033
Proceeds from factoring	55	1,038
Proceeds from warrant exercises	100	0
Payments of principal on finance leases	(121)	(94)
Proceeds from related party advances	0	125
Net Cash Flows Provided by Financing Activities	5,104	3,365
Effect of Exchange Rates on Cash	14	(12)
Net Change in Cash During Period	865	(2,173)
Cash at Beginning of Period	619	2,437
Cash at End of Period	1,484	264
Supplemental Information:
Cash paid for interest	2,045	1,434
Non-cash Investing and Financing Activities:
Reclassification of warrant liability due to cashless warrant exercise	2,167	2,030
Warrants issued in conjunction with senior secured promissory note payable	2,654	0
Common shares issued in conjunction with senior secured promissory note payable	3,720	0
Embedded conversion option with issuances of convertible debt	0	2,740
Warrant issuance in conjunction with convertible debt	$ 0	$ 758

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	6 Months Ended
Nature of the Business and Basis of Presentation	Jun. 30, 2022
Nature of the Business and Basis of Presentation [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation SANUWAVE Health, Inc. and Subsidiaries (“SANUWAVE” or the “Company”) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device used for treating diabetic foot ulcers. Through the Company’s acquisition, on August 6, 2020, of the UltraMIST® assets from Celularity, Inc. (“Celularity”), SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market. Basis of Presentation – The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. Certain accounts in the prior period condensed consolidated financial statements have been reclassified to conform to the presentation of the current period condensed consolidated financial statements. These reclassifications had no effect on the previously reported operating results. The financial information as of June 30, 2022, and for the three and six months ended June 30 June 30 The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited Consolidated Financial Statements at that date but does not include all of the information and disclosures required by U.S. GAAP for comprehensive financial statements. These financial statements should be read in conjunction with the Company’s December 31, 2021 Annual Report on Form 10-K filed with the SEC on May 13, 2022 (the “2021 Annual Report”).

Going Concern

Going Concern	6 Months Ended
Going Concern	Jun. 30, 2022
Going Concern [Abstract]
Going Concern	2. Going Concern Our recurring losses from operations and dependency upon future issuances of equity or other financing to fund ongoing operations have raised substantial doubt as to our ability to continue as a going concern. We will be required to raise additional funds to finance our operations and remain a going concern; we may not be able to do so, and/or the terms of any financings may not be advantageous to us. The continuation of our business is dependent upon raising additional capital. We expect to devote substantial resources for the commercialization of the dermaPACE and will continue to research and develop the non-medical uses of the PACE technology, both of which will require additional capital resources. The operating losses and the events of default on the Company’s notes payable indicate substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this Form 10-Q. The continuation of our business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital in 2022 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders. In addition, there can be no assurances that our plans to obtain additional capital will be successful on the terms or timeline we expect, or at all. Although no assurances can be given, management believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for us. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or obtain funds through financing transactions with unfavorable terms. The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Our consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Significant accounting policies followed by the Company are summarized below and should be read in conjunction with those described in Note 3 to the Consolidated Financial Statements in our 2021 Annual Report. Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation, and the estimated fair value of financial instruments, including warrants and embedded conversion options.

Income (Loss) per Share

Income (Loss) per Share	6 Months Ended
Income (Loss) per Share	Jun. 30, 2022
Income (Loss) per Share [Abstract]
Income (Loss) per Share	4. Income (Loss) per Share The net income (loss) per share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares outstanding for the three and six months ended June 30, 2022, and 2021. In accordance with ASC Topic 260-10-45-13, Earnings Per Share Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows (shares in thousands): Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Weighted average shares outstanding Common shares 518,074 481,620 508,399 481,620 Common shares issuable assuming excercise of nominally priced warrants 20,486 36,691 24,191 36,780 Weighted average shares outstanding 538,560 518,311 532,590 518,400 Diluted net income (loss) per share would be computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net loss per share. As a result of the net income for the three months ended June 30, 2022, all dilutive shares were included in the computation of diluted net income per share. Anti-dilutive equity securities consist of the following for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 June 30, 2021 Common stock options 22,046 31,760 Common stock purchase warrants 189,157 150,202 Convertible notes payable 122,271 74,155 333,474 256,117

Accrued Expenses

Accrued Expenses	6 Months Ended
Accrued Expenses	Jun. 30, 2022
Accrued Expenses [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consist of the following at June and December (in s): 2022 2021 Registration penalties $ 2,190 $ 1,950 License fees 893 893 Board of director's fees 996 507 Other 1,821 1,044 $ 5,900 $ 4,394 There was no activity in the warranty reserve during the months ended June

Revenue

Revenue	6 Months Ended
Revenue	Jun. 30, 2022
Revenue [Abstract]
Revenue	6. Revenue Disaggregation of Revenue - The disaggregation of revenue is based on geographical region. All revenue is recognized at the point in time when control is transferred to our clients. The following tables present revenue from contracts with customers for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 United States International Total United States International Total Accessories and parts $ 2,636 $ 34 $ 2,670 $ 1,938 $ 70 $ 2,008 Product 863 - 863 470 44 514 License fees and other - 5 5 91 20 111 Topic 606 Revenue $ 3,499 $ 39 $ 3,538 $ 2,499 $ 134 $ 2,633 Rental income 344 - 344 276 - 276 Topic 842 Revenue $ 344 $ - $ 344 $ 276 $ - $ 276 Total Revenue $ 3,843 $ 39 $ 3,882 $ 2,775 $ 134 $ 2,909 Six Months Ended June 30, 2022 Six Months Ended June 30, 2021 United States International Total United States International Total Accessories and parts $ 4,767 $ 30 $ 4,797 $ 3,373 $ 206 $ 3,579 Product 1,554 16 1,570 511 256 767 License fees and other 8 14 22 124 25 149 Topic 606 Revenue $ 6,329 $ 60 $ 6,389 $ 4,008 $ 487 $ 4,495 Rental income 688 - 688 530 - 530 Topic 842 Revenue $ 688 $ - $ 688 $ 530 $ - $ 530 Total Revenue $ 7,017 $ 60 $ 7,077 $ 4,538 $ 487 $ 5,025 Contract liabilities - As of June 30, 2022 and December 31, 2021 the Company has contract liabilities from contracts with customers as follows (in thousands): June 30, 2022 December 31, 2021 Service agreements $ 359 $ 137 Deposit on future equipment purchases - 204 Total contract liabilities 359 341 Less: current portion (64 ) (48 ) Non-current contract liabilities $ 295 $ 293 During the three months ended June 30, 2022 and 2021 the Company recognized revenue related to these contrat liabilities of $10 thousand and $8 thousand, respectively, that were included in the beginning contract liability balances for each of those periods. During the six months ended June 30, 2022 and 2021 the Company recognized revenue related to these contract liabilities of $18 thousand and $16 thousand, respectively, that were included in the beginning contract liability balances for each of those periods The following table summarizes the changes in contract liabilities during the and six months ended June (in s): Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Beginning balance $ 361 $ 187 $ 341 $ 69 New service agreement additions 8 35 36 36 Deposit on future equipment purchases - - - 125 Revenue recognized (10 ) (8 ) (18 ) (16 ) Total contract liabilities 359 214 359 214 Less current portion (64 ) (33 ) (64 ) (33 ) Non-current contract liabilities $ 295 $ 181 $ 295 $ 181

Concentration of Credit Risk an

Concentration of Credit Risk and Limited Suppliers	6 Months Ended
Concentration of Credit Risk and Limited Suppliers	Jun. 30, 2022
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration of Credit Risk and Limited Suppliers	7. Concentration of Credit Risk and Limited Suppliers Major customers are defined as customers whose accounts receivable, or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable from major customers of the Company for the periods indicated were as follows: June 30, 2022 December 31, 2021 Accounts Receivable: Customer A 14% 16% Customer B 13% n/a Customer C n/a 24% The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The of purchases from major vendors of the Company that exceeded of total purchases for the and six months ended June and were as follows: Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Purchases: Vendor A 17% 44% 18% 43% Vendor B n/a 38% n/a 21%

Notes Payable

Notes Payable	6 Months Ended
Notes Payable	Jun. 30, 2022
Notes Payable [Abstract]
Notes Payable	8. Notes payable The following tables summarize outstanding notes payable as of June and December (dollars in s): A s of 06 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.50 % n/a $ 18,000 (5,666 ) - $ 12,334 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.0538 6,445 (140 ) 218 6,523 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts In default n/a n/a 812 (414 ) - 398 Short-term bridge loan October 31, 2022 5.00 % n/a 1,559 (75 ) - 1,484 Total debt outstanding, including amounts in default 29,445 (6,295 ) 218 23,368 Less: current maturities, including notes in default (28,684 ) 6,295 (218 ) (22,607 ) Total long-term debt as of June $ 761 $ - $ - $ 761 As of 12 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.25 % n/a $ 15,000 (3,414 ) - $ 11,586 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.1071 6,445 (1,099 ) 6,255 11,601 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts March 11, 2022 n/a n/a 1,500 (1,054 ) - 446 Total debt outstanding, including amounts in default 25,574 (5,567 ) 6,255 26,262 Less: current maturities, including notes in default (24,699 ) 5,567 (6,255 ) (25,387 ) Total long-term debt as of December $ 875 $ - $ - $ 875 Senior secured promissory note payable, in default (“Senior Secured Note”) - On February the Company entered into a Note Extension with NH Expansion Credit Fund Holdings LP. The amount of the note was , with an interest rate of and matures on September 30, 2025 Because the combined fair value of the applicable warrants and common stock issued as part of this note exceeded the face value of the note, the additional amount beyond the face value is recorded as a loss on issuance of . Senior secured promissory note payable, in default (“Senior Secured Note-Third Amendment) – On June 30, 2022, the Company entered into the Third Amendment to the Note and Warrant Purchase and Security Agreement (the “Third NWPSA”), which amends that certain Second Amendment to the Note and Warrant Purchase and Security Agreement, dated as of February 25, 2022, (as amended, the “NWPSA”). The Third NWPSA provides for (i) the extension of the Agent’s and Holder’s forbearance of exercising their remedies arising from Existing Defaults (as defined in the NWPSA) to the earlier of (x) the occurrence of an Event of Default and (y) August 30, 2022, and (ii) the extension to file a registration statement with the Securities and Exchange Commission (“SEC”) to register the resale of the Advisor Shares (as defined in the NWPSA) no later than August 30, 2022. May 2022 Advance on Future Receipts Financing In conjunction with the 24-week agreement, the Company is obligated to remit to GCF a minimum of $59 thousand of receipts each week for the twenty-four weeks. The Company will begin making the required minimum weekly payments May 23, 2022, and is obligated to continue through October 31, 2022. Because the combined fair value of the applicable warrants issued as part of this note exceeded the original payoff value of the note, the additional amount beyond the face value is recorded as a loss on extinguishment of $211 thousand. On June 28, 2022, the Company entered into short-term loan from a group of investors in the amount of $1.5 million. The interest rate on this loan is 5% and the expiration date is October 31, 2022. Embedded Conversion Option Liability The fair value of Conversion Option liability was determined by using a binomial pricing model: At / / At / / Conversion Price (1) $ 0.05 $ 0.11 Interest Rate (annual) (2) 1.28 % 0.18 % Volatility (annual) (3) 125.00 % 289.65 % Time to Maturity (Years) 0.05 0.50 (1) Based on the terms provided in the warrant agreement to purchase common stock of the Company as of June and December (2) (3)

Common Stock Purchase Warrants

Common Stock Purchase Warrants	6 Months Ended
Common Stock Purchase Warrants	Jun. 30, 2022
Common Stock Purchase Warrants [Abstract]
Common Stock Purchase Warrants	9. Common Stock Purchase Warrants A summary of the warrant activity as of June is as follows (dollars in s): Warrants Weighted Average Exercise Price per share Weighted Average Remaining Contractual Life (years) Outstanding at December 204,882,664 $ 0.20 2.54 Exercised (15,909,091 ) 0.01 Issued 21,874,302 0.18 Outstanding at June 210,847,875 $ 0.21 2.44 On January the Company issued 14,000,000 shares of its common stock to LGH upon the cashless exercise of of the LGH Warrants under the terms of the warrant agreement. After this cashless exercise, of LGH Warrants remain outstanding. On February the Company issued 16.1 warrants with an exercise price of and a -year term as part of the Amendment to Note and Warrant Purchase and Security Agreement with NH Expansion Fund.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 30, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	10. Fair Value Measurements In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the outstanding warrants and certain embedded conversion features associated with a convertible debt on a recurring basis to determine the fair value of the liability. The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of June 30, 2022 and December 31, 2021 (in thousands): Fair value measured at June 30, 2022 Fair value at June 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 5,295 $ - $ - $ 5,295 Embedded conversion option 218 - - 218 Total fair value 5,513 - - 5,513 Fair value measured at December 31, 2021 Fair value at December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 9,614 - - 9,614 Embedded conversion option 6,255 - - 6,255 Total fair value 15,869 - - 15,869 There were no transfers between Level 1, 2 or 3 during the three and six months ended June 30, 2022 and 2021. The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g. changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (dollars in thousands): Warrant Liability Conversion Feature Total Balance at December 31, 2021 $ 9,614 $ 6,255 $ 15,869 Cashless exercise (2,167 ) - (2,167 ) Warrants issued 3,168 - 3,168 Change in fair value (5,320 ) (6,037 ) (11,357 ) Balance at June 30 2022 $ 5,295 $ 218 $ 5,513 A summary of the warrant liability activity for the six months ended June 30, 2022 is as follows: Warrants Outstanding Fair Value per Share Fair Value Balance at December 31, 2021 62,617,188 $ 0.15 $ 9,614,134 Warrants classified as liabilities (15,000,000 ) 0.14 (2,167,022 ) Warrants issued 21,874,302 0.14 3,168,581 Gain on remeasurement of warrant liability - (5,320,470 ) Balance at June 30 2022 69,491,490 $ 0.08 $ 5,295,223 Significant inputs related to the Company’s liability classified warrants are listed below. June 30, 2022 December 31, 2021 New Issuance at Issue Date Weighted average remaining life in years 5.21 4.67 6.89 Weighted average volatility 325 % 116 % 276 % Weighted average risk free interest rate 3.0 % 1.2 % 3.0 % Expected dividend yield 0.00 % 0.00 % 0.00 %

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2022
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies In the ordinary course of business, the Company from time to time becomes involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Companies expenses legal fees in the period in which they are occurred. Supplier disputes

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions Advance from Director June 2022 dermaPACE® Purchase – On June 30, 2022, the Company purchased unused dermaPACE® equipment and applicator inventory from PSWC for $265 thousand. As of June 30, 2022, there is $424 thousand in the condensed consolidated balance sheets related to this and other transactions of the same nature. Short-term loan – On June 28, 2022, the Company entered into a short-term loan with a group of investors (see Footnote 8 – Notes Payable). Of that investing group, $50 thousand was received by Ian Miller, also a member of the board of directors.

Subsequent Events

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events SBA loan #2 – In June the Company submitted the loan forgiveness application for the SBA loan #2 and on July 8, 2022, the Company received confirmation that the loan forgiveness application has been approved. At June 30, 2022, the loan balance was $1.0 million Securities Purchase Agreement and Future Advance Convertible Promissory Notes On August 5, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”), with the purchasers identified on the signature pages thereto (the “Purchasers”) for the sale by the Company in a private placement (the “Private Placement”) of (i) the Company’s future advance convertible promissory notes in an aggregate principal amount of approximately $16.1 million (the “Notes”), consisting of approximately $12.2 million in newly raised capital and $3.8 million in rolled forward accrued expenses and fees, (ii) warrants to purchase an approximate additional 403 million shares of common stock of the Company with an exercise price of $0.067 per share (the “First Warrants”) and (iii) warrants to purchase an approximate additional 403 million shares of common stock of the Company with an exercise price of $0.04 per share (the “Second Warrants,” collectively with the First Warrants, the "Warrants"). The Notes will be convertible and the Warrants exercisable on the earlier to occur of (1) completion of a reverse stock split and (2) December 31, 2022. The exercise price of the Warrants is subject to adjustment, including if the Company issues or sells shares of common stock or Share Equivalents (as defined in the Warrants) for an effective consideration price less than the exercise price of the Warrants or if the Company lists its shares of common stock on the Nasdaq Capital Market and the average volume weighted average price of such common stock for the five In connection with Private Placement of these Notes, Kestrel Merchant Partners and WestPark Capital received cash fees and certain expenses. Payment of Leviston and Five Party notes On August 5, 2022 in exchange for all outstanding amounts owed and the retirement of the associated warrants under the Securities Purchase Agreement, dated April 20, 2021 with Leviston Resources LLC and the Securities Purchase Agreements with five other noteholders. The Company paid $3.9 million and issued 19.4 million shares of

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2022
Summary of Significant Accounting Policies [Abstract]
Estimates	Estimates Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes, estimated fair value of stock-based compensation, and the estimated fair value of financial instruments, including warrants and embedded conversion options.

Income (Loss) per Share (Tables

Income (Loss) per Share (Tables)	6 Months Ended
Income (Loss) per Share (Tables)	Jun. 30, 2022
Income (Loss) per Share [Abstract]
Weighted Average Shares Outstanding	Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows (shares in thousands): Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Weighted average shares outstanding Common shares 518,074 481,620 508,399 481,620 Common shares issuable assuming excercise of nominally priced warrants 20,486 36,691 24,191 36,780 Weighted average shares outstanding 538,560 518,311 532,590 518,400
Anti-dilutive Equity Securities	Anti-dilutive equity securities consist of the following for the six months ended June 30, 2022 and 2021, respectively (in thousands): Six Months Ended June 30, 2022 June 30, 2021 Common stock options 22,046 31,760 Common stock purchase warrants 189,157 150,202 Convertible notes payable 122,271 74,155 333,474 256,117

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
Accrued Expenses (Tables)	Jun. 30, 2022
Accrued Expenses [Abstract]
Accrued Expenses	Accrued expenses consist of the following at June and December (in s): 2022 2021 Registration penalties $ 2,190 $ 1,950 License fees 893 893 Board of director's fees 996 507 Other 1,821 1,044 $ 5,900 $ 4,394

Revenue (Tables)

Revenue (Tables)	6 Months Ended
Revenue (Tables)	Jun. 30, 2022
Revenue [Abstract]
Disaggregation of Revenue	The disaggregation of revenue is based on geographical region. All revenue is recognized at the point in time when control is transferred to our clients. The following tables present revenue from contracts with customers for the three and six months ended June 30, 2022 and 2021 (in thousands): Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 United States International Total United States International Total Accessories and parts $ 2,636 $ 34 $ 2,670 $ 1,938 $ 70 $ 2,008 Product 863 - 863 470 44 514 License fees and other - 5 5 91 20 111 Topic 606 Revenue $ 3,499 $ 39 $ 3,538 $ 2,499 $ 134 $ 2,633 Rental income 344 - 344 276 - 276 Topic 842 Revenue $ 344 $ - $ 344 $ 276 $ - $ 276 Total Revenue $ 3,843 $ 39 $ 3,882 $ 2,775 $ 134 $ 2,909 Six Months Ended June 30, 2022 Six Months Ended June 30, 2021 United States International Total United States International Total Accessories and parts $ 4,767 $ 30 $ 4,797 $ 3,373 $ 206 $ 3,579 Product 1,554 16 1,570 511 256 767 License fees and other 8 14 22 124 25 149 Topic 606 Revenue $ 6,329 $ 60 $ 6,389 $ 4,008 $ 487 $ 4,495 Rental income 688 - 688 530 - 530 Topic 842 Revenue $ 688 $ - $ 688 $ 530 $ - $ 530 Total Revenue $ 7,017 $ 60 $ 7,077 $ 4,538 $ 487 $ 5,025
Contract Liabilities	As of June 30, 2022 and December 31, 2021 the Company has contract liabilities from contracts with customers as follows (in thousands): June 30, 2022 December 31, 2021 Service agreements $ 359 $ 137 Deposit on future equipment purchases - 204 Total contract liabilities 359 341 Less: current portion (64 ) (48 ) Non-current contract liabilities $ 295 $ 293 The following table summarizes the changes in contract liabilities during the and six months ended June (in s): Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Beginning balance $ 361 $ 187 $ 341 $ 69 New service agreement additions 8 35 36 36 Deposit on future equipment purchases - - - 125 Revenue recognized (10 ) (8 ) (18 ) (16 ) Total contract liabilities 359 214 359 214 Less current portion (64 ) (33 ) (64 ) (33 ) Non-current contract liabilities $ 295 $ 181 $ 295 $ 181

Concentration of Credit Risk _2

Concentration of Credit Risk and Limited Suppliers (Tables)	6 Months Ended
Concentration of Credit Risk and Limited Suppliers (Tables)	Jun. 30, 2022
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration of Credit Risk and Limited Suppliers	Major customers are defined as customers whose accounts receivable, or sales individually consist of more than ten percent of total trade receivables or total sales, respectively. The percentage of accounts receivable from major customers of the Company for the periods indicated were as follows: June 30, 2022 December 31, 2021 Accounts Receivable: Customer A 14% 16% Customer B 13% n/a Customer C n/a 24% The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. The of purchases from major vendors of the Company that exceeded of total purchases for the and six months ended June and were as follows: Three Months Ended Six Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Purchases: Vendor A 17% 44% 18% 43% Vendor B n/a 38% n/a 21%

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
Notes Payable (Tables)	Jun. 30, 2022
Notes Payable [Abstract]
Outstanding Notes Payable	The following tables summarize outstanding notes payable as of June and December (dollars in s): A s of 06 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.50 % n/a $ 18,000 (5,666 ) - $ 12,334 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.0538 6,445 (140 ) 218 6,523 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts In default n/a n/a 812 (414 ) - 398 Short-term bridge loan October 31, 2022 5.00 % n/a 1,559 (75 ) - 1,484 Total debt outstanding, including amounts in default 29,445 (6,295 ) 218 23,368 Less: current maturities, including notes in default (28,684 ) 6,295 (218 ) (22,607 ) Total long-term debt as of June $ 761 $ - $ - $ 761 As of 12 / / (dollars in s) Maturity Date Interest Rate Conversion Price Principal Remaining Debt Discount Remaining Embedded Conversion Option Carrying Value Senior secured promissory note payable, in default In default 20.25 % n/a $ 15,000 (3,414 ) - $ 11,586 Convertible promissory notes payable, in default: Total convertible promisory notes payable, in default In default 15.40 % $ 0.1071 6,445 (1,099 ) 6,255 11,601 Convertible promissory notes payable, related parties, in default: Total convertible promisory notes payable, related parties, in default In default 14.0 % $ 0.10 1,596 - - 1,596 SBA loan # February 20, 2026 1.00 % n/a 1,033 - - 1,033 Advances on future cash receipts March 11, 2022 n/a n/a 1,500 (1,054 ) - 446 Total debt outstanding, including amounts in default 25,574 (5,567 ) 6,255 26,262 Less: current maturities, including notes in default (24,699 ) 5,567 (6,255 ) (25,387 ) Total long-term debt as of December $ 875 $ - $ - $ 875
Fair Value of Conversion Option liability	The fair value of Conversion Option liability was determined by using a binomial pricing model: At / / At / / Conversion Price (1) $ 0.05 $ 0.11 Interest Rate (annual) (2) 1.28 % 0.18 % Volatility (annual) (3) 125.00 % 289.65 % Time to Maturity (Years) 0.05 0.50 (1) Based on the terms provided in the warrant agreement to purchase common stock of the Company as of June and December (2) (3)

Common Stock Purchase Warrants

Common Stock Purchase Warrants (Tables)	6 Months Ended
Common Stock Purchase Warrants (Tables)	Jun. 30, 2022
Common Stock Purchase Warrants [Abstract]
Warrant Activity	A summary of the warrant activity as of June is as follows (dollars in s): Warrants Weighted Average Exercise Price per share Weighted Average Remaining Contractual Life (years) Outstanding at December 204,882,664 $ 0.20 2.54 Exercised (15,909,091 ) 0.01 Issued 21,874,302 0.18 Outstanding at June 210,847,875 $ 0.21 2.44

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 30, 2022
Fair Value Measurements [Abstract]
Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of June 30, 2022 and December 31, 2021 (in thousands): Fair value measured at June 30, 2022 Fair value at June 30, 2022 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 5,295 $ - $ - $ 5,295 Embedded conversion option 218 - - 218 Total fair value 5,513 - - 5,513 Fair value measured at December 31, 2021 Fair value at December 31, 2021 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Warrant liability $ 9,614 - - 9,614 Embedded conversion option 6,255 - - 6,255 Total fair value 15,869 - - 15,869
Warrants Outstanding and Fair Values	The following table presents changes in Level 3 liabilities measured at fair value for the six months ended June 30, 2022. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g. changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs (dollars in thousands): Warrant Liability Conversion Feature Total Balance at December 31, 2021 $ 9,614 $ 6,255 $ 15,869 Cashless exercise (2,167 ) - (2,167 ) Warrants issued 3,168 - 3,168 Change in fair value (5,320 ) (6,037 ) (11,357 ) Balance at June 30 2022 $ 5,295 $ 218 $ 5,513 A summary of the warrant liability activity for the six months ended June 30, 2022 is as follows: Warrants Outstanding Fair Value per Share Fair Value Balance at December 31, 2021 62,617,188 $ 0.15 $ 9,614,134 Warrants classified as liabilities (15,000,000 ) 0.14 (2,167,022 ) Warrants issued 21,874,302 0.14 3,168,581 Gain on remeasurement of warrant liability - (5,320,470 ) Balance at June 30 2022 69,491,490 $ 0.08 $ 5,295,223
Fair Value of Warrant Liabilities Using Black-Scholes Model	Significant inputs related to the Company’s liability classified warrants are listed below. June 30, 2022 December 31, 2021 New Issuance at Issue Date Weighted average remaining life in years 5.21 4.67 6.89 Weighted average volatility 325 % 116 % 276 % Weighted average risk free interest rate 3.0 % 1.2 % 3.0 % Expected dividend yield 0.00 % 0.00 % 0.00 %

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Details)	Aug. 06, 2020 Product
Nature of the Business and Basis of Presentation [Abstract]
Number of energy transfer technology products	2
Number of human tissues biological products	2

Income (Loss) per Share, Weight

Income (Loss) per Share, Weighted Average Shares Outstanding (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding basic (in shares)	538,560,051	518,310,781	532,589,825	518,400,008
Warrant exercise price (in dollars per share)			$ 0.01
Common Shares [Member]
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding basic (in shares)	518,074,000	481,620,000	508,399,000	481,620,000
Common Shares Issuable Assuming Exercise of Nominally Priced Warrants [Member]
Weighted Average Shares Outstanding [Abstract]
Weighted average shares outstanding basic (in shares)	20,486,000	36,691,000	24,191,000	36,780,000

Income (Loss) per Share, Anti D

Income (Loss) per Share, Anti Dilutive Equity Securities (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	333,474	256,117
Common Stock Options [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	22,046	31,760
Common Stock Purchase Warrants [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	189,157	150,202
Convertible Notes Payable [Member]
Anti-dilutive Securities [Abstract]
Anti-dilutive equity securities (in shares)	122,271	74,155

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	6 Months Ended
Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accrued Expense [Abstract]
Registration penalties	$ 2,190	$ 1,950
License fees	893	893
Board of director's fees	996	507
Other	1,821	1,044
Total accrued expenses	5,900	$ 4,394
Warranty reserve accrual	$ 0

Revenue, Disaggregation of Reve

Revenue, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Abstract]
Revenue	$ 3,538	$ 2,633	$ 6,389	$ 4,495
Rental income	344	276	688	530
Total Revenues	3,882	2,909	7,077	5,025
Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenue	2,670	2,008	4,797	3,579
Product [Member]
Disaggregation of Revenue [Abstract]
Revenue	863	514	1,570	767
Total Revenues	862	514	1,507	767
License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenue	5	111	22	149
United States [Member]
Disaggregation of Revenue [Abstract]
Revenue	3,499	2,499	6,329	4,008
Rental income	344	276	688	530
Total Revenues	3,843	2,775	7,017	4,538
United States [Member] \| Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenue	2,636	1,938	4,767	3,373
United States [Member] \| Product [Member]
Disaggregation of Revenue [Abstract]
Revenue	863	470	1,554	511
United States [Member] \| License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenue	0	91	8	124
International [Member]
Disaggregation of Revenue [Abstract]
Revenue	39	134	60	487
Rental income	0	0	0	0
Total Revenues	39	134	60	487
International [Member] \| Accessories and Parts [Member]
Disaggregation of Revenue [Abstract]
Revenue	34	70	30	206
International [Member] \| Product [Member]
Disaggregation of Revenue [Abstract]
Revenue	0	44	16	256
International [Member] \| License Fees and Other [Member]
Disaggregation of Revenue [Abstract]
Revenue	$ 5	$ 20	$ 14	$ 25

Revenue, Contract Liabilities (

Revenue, Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Contract liabilities [Abstract]
Beginning balance	$ 361	$ 187	$ 341	$ 69
New service agreement additions	8	35	36	36
Deposit on future equipment purchases	0	0	0	125
Revenue recognized	(10)	(8)	(18)	(16)
Total contract liabilities	359	214	359	214
Less: current portion	(64)	(33)	(64)	(33)	$ (48)
Non-current contract liabilities	295	181	295	181	$ 293
Revenue related to contract liabilities	(10)	$ (8)	(18)	$ (16)
Service Agreements [Member]
Contract liabilities [Abstract]
Beginning balance			137
Total contract liabilities	359		359
Deposit on Future Equipment Purchases [Member]
Contract liabilities [Abstract]
Beginning balance			204
Total contract liabilities	$ 0		$ 0

Concentration of Credit Risk _3

Concentration of Credit Risk and Limited Suppliers (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer A [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage			14%		16%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer B [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage			13%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer C [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage					24%
Purchases [Member] \| Supplier Concentration Risk [Member] \| Vendor A [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage	17%	44%	18%	43%
Purchases [Member] \| Supplier Concentration Risk [Member] \| Vendor B [Member]
Concentration of Credit Risk and Limited Suppliers [Abstract]
Concentration risk, percentage		38%		21%

Notes Payable, Outstanding Note

Notes Payable, Outstanding Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Senior Secured Promissory Notes Payable [Abstract]
Long-term debt gross	$ 29,445	$ 25,574
Long-term debt gross, current	(28,684)	(24,699)
Long-term debt gross, noncurrent	761	875
Remaining debt discount	(6,295)	(5,567)
Senior secured promissory note payable, in default	12,334	11,586
Remaining debt discount, current	6,295	5,567
Remaining debt discount, noncurrent	0	0
Remaining embedded conversion option	218	6,255
Remaining embedded conversion option, current	(218)	(6,255)
Remaining embedded conversion option, noncurrent	0	0
Convertible promissory note payable, in default	6,523	11,601
Advances on future cash receipts	398	446
Short-term bridge loan	1,484	0
Debt, Long-term and Short-term, Combined Amount [Abstract]
Long-term debt net	23,368	26,262
Long-term debt net, current	(22,607)	(25,387)
Long-term debt net, noncurrent	$ 761	$ 875
Convertible Notes Payable [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	In default	In default
Interest rate	14%	14%
Conversion price (in dollars per share)	$ 0.10	$ 0.10
Principal amount	$ 1,596	$ 1,596
Remaining debt discount	0	0
Remaining embedded conversion option	0	0
Convertible promissory notes payable, related parties, in default	$ 1,596	$ 1,596
Short-Term Bridge Loan [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	Oct. 31, 2022
Interest rate	5%
Principal amount	$ 1,559
Remaining debt discount	(75)
Remaining embedded conversion option	0
Short-term bridge loan	$ 1,484
SBA Loan #2 [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	Feb. 20, 2026	Feb. 20, 2026
Interest rate	1%	1%
Principal amount	$ 1,033	$ 1,033
Remaining debt discount	0	0
Remaining embedded conversion option	0	0
SBA loans	$ 1,033	$ 1,033
Advances on Future Cash Receipts [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	In default
Maturity date		Mar. 11, 2022
Principal amount	$ 812	$ 1,500
Remaining debt discount	(414)	(1,054)
Remaining embedded conversion option	0	0
Advances on future cash receipts	$ 398	$ 446
Senior Secured Note [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	In default	In default
Interest rate	20.50%	20.25%
Principal amount	$ 18,000	$ 15,000
Remaining debt discount	(5,666)	(3,414)
Senior secured promissory note payable, in default	12,334	11,586
Remaining embedded conversion option	$ 0	$ 0
Convertible Debt [Member]
Senior Secured Promissory Notes Payable [Abstract]
Maturity date	In default	In default
Interest rate	15.40%	15.40%
Conversion price (in dollars per share)	$ 0.0538	$ 0.1071
Principal amount	$ 6,445	$ 6,445
Remaining debt discount	(140)	(1,099)
Remaining embedded conversion option	218	6,255
Convertible promissory note payable, in default	$ 6,523	$ 11,601

Notes Payable, Senior Secured P

Notes Payable, Senior Secured Promissory Note Payable, in Default (Details) $ in Thousands		3 Months Ended		6 Months Ended
	May 19, 2022 USD ($) wk	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Feb. 25, 2022 USD ($)	Dec. 31, 2021 USD ($)
Senior Secured Promissory Notes Payable [Abstract]
Loss on extinguishment of debt		$ 211	$ 0	$ 211	$ 0
Short-term loans		1,484		1,484			$ 0
May 2022 Advances on Future Receipts Financing [Member]
Senior Secured Promissory Notes Payable [Abstract]
Balance paid	$ 400
Cash proceeds	545
Sale of future receipts	$ 1,000
Non-recourse agreement term \| wk	24
Minimum amount of receipts, payment	$ 59
Receipts of remaining term \| wk	24
Loss on extinguishment of debt				211
Short-Term Bridge Loan [Member]
Senior Secured Promissory Notes Payable [Abstract]
Principal amount		$ 1,559		$ 1,559
Interest rate		5%		5%
Maturity date				Oct. 31, 2022
Short-term loans		$ 1,484		$ 1,484
Senior Secured Note [Member]
Senior Secured Promissory Notes Payable [Abstract]
Principal amount		$ 18,000		$ 18,000			$ 15,000
Interest rate		20.50%		20.50%			20.25%
Senior Secured Note [Member] \| NH Expansion Credit Fund Holdings LP [Member]
Senior Secured Promissory Notes Payable [Abstract]
Principal amount						$ 3,000
Interest rate						20.50%
Maturity date				Sep. 30, 2025
Loss on issuance						$ 3,400

Notes Payable, Embedded Convers

Notes Payable, Embedded Conversion Option Liability (Details) - Binomial Pricing Model [Member]		6 Months Ended	12 Months Ended
		Jun. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares
Measurement Input, Conversion Price [Member]
Embedded Conversion Option Liability [Abstract]
Conversion Price (in dollars per share)	[1]	$ 0.05	$ 0.11
Measurement Input, Interest Rate (annual) [Member]
Embedded Conversion Option Liability [Abstract]
Measurement input	[2]	0.0128	0.0018
Measurement Input, Volatility (annual) [Member]
Embedded Conversion Option Liability [Abstract]
Measurement input	[3]	1.2500	2.8965
Measurement Input, Time to Maturity (Years) [Member]
Embedded Conversion Option Liability [Abstract]
Time to Maturity (Years)		18 days	6 months

[1]Based on the terms provided in the warrant agreement to purchase common stock of the Company as of June 30, 2022 and December 31, 2021.[2]Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve.[3]Based on the historical daily volatility of the Company as of each presented period ending date.

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants (Details) - $ / shares			6 Months Ended	12 Months Ended
Common Stock Purchase Warrants (Details) - $ / shares	Feb. 28, 2022	Jan. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Warrants [Abstract]
Outstanding, beginning (in shares)			204,882,664
Exercised (in shares)			(15,909,091)
Issued (in shares)			21,874,302
Outstanding, ending (in shares)			210,847,875	204,882,664
Weighted Average Exercise Price per share [Abstract]
Outstanding, beginning (in dollars per share)			$ 0.20
Exercised (in dollars per share)			0.01
Issued (in dollars per share)			0.18
Outstanding, ending (in dollars per share)			$ 0.21	$ 0.20
Weighted Average Remaining Contractual Life (Years) [Abstract]
Weighted Average Remaining Contractual Life (years)			2 years 5 months 8 days	2 years 6 months 14 days
Issued (in shares)			21,874,302
NH Expansion Fund [Member]
Weighted Average Exercise Price per share [Abstract]
Outstanding, ending (in dollars per share)	$ 0.18
Weighted Average Remaining Contractual Life (Years) [Abstract]
Issued (in shares)	16,100,000
Warrants term Period			8 years 7 months 6 days
LGH Warrants [Member]
Warrants [Abstract]
Exercised (in shares)		(15,000,000)
Outstanding, ending (in shares)		8,600,000
Weighted Average Remaining Contractual Life (Years) [Abstract]
Issued (in shares)		14,000,000

Fair Value Measurements, Liabil

Fair Value Measurements, Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]
Transfer to level 3	$ 0	$ 0	$ 0	$ 0
Transfer from level 3	0	$ 0	0	$ 0
Recurring [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	5,513		5,513		$ 15,869
Recurring [Member] \| Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	5,295		5,295		9,614
Recurring [Member] \| Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	218		218		6,255
Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0		0
Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member] \| Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0		0
Recurring [Member] \| Quoted Prices in Active Markets (Level 1) [Member] \| Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0		0
Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0		0
Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member] \| Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0		0
Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member] \| Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	0		0		0
Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	5,513		5,513		15,869
Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member] \| Warrant Liability [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	5,295		5,295		9,614
Recurring [Member] \| Significant Unobservable Inputs (Level 3) [Member] \| Embedded Conversion Option [Member]
Financial Liabilities Fair Value Disclosure [Abstract]
Liabilities at fair value	$ 218		$ 218		$ 6,255

Fair Value Measurements, Warran

Fair Value Measurements, Warrants Fair Value, Outstanding and Valuation Model (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Feb. 28, 2022	Dec. 31, 2021 USD ($) $ / shares shares
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	$ 5,295,223		$ 9,614,134
Warrants issued	3,168,581
Gain on remeasurement of warrant liability	$ (5,320,470)
Warrant Outstanding and Fair Value [Abstract]
Warrants outstanding (in shares) \| shares	69,491,490		62,617,188
Warrants issued (in shares) \| shares	21,874,302
Warrants issued (in dollars per share) \| $ / shares	$ 0.14
Gain on remeasurement of warrant liability (in shares) \| shares	0
Fair value per share (in dollars per share) \| $ / shares	$ 0.08		$ 0.15
Measurement Input, Weighted Average Expected Life in Years [Member]
Black Scholes Option Pricing Model [Abstract]
Weighted average expected life in years (Years)	5 years 2 months 15 days	6 years 10 months 20 days	4 years 8 months 1 day
Measurement Input, Weighted Average Volatility (annual) [Member]
Black Scholes Option Pricing Model [Abstract]
Warrants measurement input	3.25	2.76	1.16
Measurement Input, Weighted Average Risk Free Interest Rate [Member]
Black Scholes Option Pricing Model [Abstract]
Warrants measurement input	0.030	0.030	0.012
Measurement Input, Expected Dividend Yield [Member]
Black Scholes Option Pricing Model [Abstract]
Warrants measurement input	0	0	0
Warrant Classified [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	$ (2,167,022)
Warrant Outstanding and Fair Value [Abstract]
Warrants outstanding (in shares) \| shares	(15,000,000)
Fair value per share (in dollars per share) \| $ / shares	$ 0.14
Level 3 [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	$ 5,513		$ 15,869
Warrants issued	3,168
Cashless exercise	(2,167)
Gain on remeasurement of warrant liability	(11,357)
Level 3 [Member] \| Warrant Liability [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	5,295		9,614
Warrants issued	3,168
Cashless exercise	(2,167)
Gain on remeasurement of warrant liability	(5,320)
Level 3 [Member] \| Conversion Feature [Member]
Fair Value, Warrant Liability [Abstract]
Warrant Liability, Fair Value	218		$ 6,255
Warrants issued	0
Cashless exercise	0
Gain on remeasurement of warrant liability	$ (6,037)

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands			6 Months Ended
	Jun. 30, 2022	Jun. 28, 2022	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Related Party Transaction Disclosures [Abstract]
Purchases	$ 424
Proceeds from short term loans			$ 2,130	$ 1,033
A. Michael Stolarski [Member] \| April 2022 Advances from Directors [Member]
Related Party Transaction Disclosures [Abstract]
Advances from related parties					$ 250
Ian Miller [Member]
Related Party Transaction Disclosures [Abstract]
Proceeds from short term loans		$ 50
PSWC [Member]
Related Party Transaction Disclosures [Abstract]
Purchases	$ 265

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions		6 Months Ended
	Aug. 05, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Subsequent Event [Abstract]
Warrant exercise price (in dollars per share)		$ 0.21		$ 0.20
Proceeds from warrant exercises		$ 100	$ 0
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] \| Subsequent Event [Member]
Subsequent Event [Abstract]
Aggregate principal amount	$ 16,100
Newly raised capital	12,200
Acrrued expenses and fees rolled forward	$ 3,800
Number of trading days	5 days
Warrants term period	5 years
Proceeds from warrant exercises	$ 14,400
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] \| Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Abstract]
Share price (in dollars per share)	$ 0.04
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] \| First Warrant [Member] \| Subsequent Event [Member]
Subsequent Event [Abstract]
Warrants to purchase common stock (in shares)	403
Warrant exercise price (in dollars per share)	$ 0.067
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] \| First Warrant [Member] \| Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Abstract]
Warrant exercise price (in dollars per share)	$ 0.01
Securities Purchase Agreement and Future Advance Convertible Promissory Notes [Member] \| Second Warrant [Member] \| Subsequent Event [Member]
Subsequent Event [Abstract]
Warrants to purchase common stock (in shares)	403
Warrant exercise price (in dollars per share)	$ 0.04
Leviston Resources LLC [Member] \| Subsequent Event [Member]
Subsequent Event [Abstract]
Cash payment	$ 3,900
Shares issued (in shares)	19.4
SBA Loan #2 [Member]
Subsequent Event [Abstract]
SBA loans		1,033		$ 1,033
Aggregate principal amount		$ 1,033		$ 1,033